S 3304 |
| Catalog No.GC32938 |
S 3304 is a novel matrix metalloproteinases (MMP) inhibitor specific for MMP-2 and MMP-9.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 203640-27-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
S-3304 is a novel matrix metalloproteinases (MMP) inhibitor specific for MMP-2 and MMP-9.
S 3304 is a novel D-tryptophan derivative and a potent, orally active, noncytotoxic Matrix metalloproteinases inhibitor (MMPI). Biochemical studies show that S 3304 most potently inhibits the activities of MMP-2 and MMP-9 but does not inhibit MMP-1, MMP-3, or MMP-7 and may, therefore, lack the musculoskeletal side effects seen with nonspecific inhibitors[1].
In vivo pharmacologic studies have shown that the oral administration of S 3304, at a dose range of 20 to 200 mg/kg, inhibits angiogenesis, artificially induced in mice by the dorsal air-sac method. Similar oral doses of S 3304 result in potent inhibition of metastatic lung colonization of Lewis murine lung carcinoma injected via tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen[1].
[1]. Chiappori AA, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *